Literature DB >> 18723844

Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

Anna T Rogojina1, John L Nitiss.   

Abstract

Topoisomerase II (Top2) is the primary target for active anti-cancer agents. We developed an efficient approach for identifying hypersensitive Top2 mutants and isolated a panel of mutants in yeast Top2 conferring hypersensitivity to the intercalator N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulphonanilide (mAMSA). Some mutants conferred hypersensitivity to etoposide as well as mAMSA, whereas other mutants exhibited hypersensitivity only to mAMSA. Two mutants in Top2, changing Pro(473) to Leu and Gly(737) to Val, conferred extraordinary hypersensitivity to mAMSA and were chosen for further characterization. The mutant proteins were purified, and their biochemical activities were assessed. Both mutants encode enzymes that are hypersensitive to inhibition by mAMSA and other intercalating agents and exhibited elevated levels of mAMSA-induced Top2:DNA covalent complexes. While Gly(737) --> Val Top2p generated elevated levels of Top2-mediated double strand breaks in vitro, the Pro(473) --> Leu mutant protein showed only a modest increase in Top2-mediated double strand breaks but much higher levels of Top2-mediated single strand breaks. In addition, the Pro(473) --> Leu mutant protein also generated high levels of mAMSA-stabilized covalent complexes in the absence of ATP. We tested the role of single strand cleavage in cell killing with alleles of Top2 that could generate single strand breaks, but not double strand breaks. Expression in yeast of a Pro(473) --> Leu mutant that could only generate single strand breaks conferred hypersensitivity to mAMSA. These results indicate that generation of single strand breaks by Top2-targeting agents can be an important component of cell killing by Top2-targeting drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723844      PMCID: PMC2570872          DOI: 10.1074/jbc.M804058200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Tumor cell death induced by topoisomerase-targeting drugs.

Authors:  T K Li; L F Liu
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

2.  Topoisomerase II-mediated cleavage of plasmid DNA.

Authors:  D A Burden; S J Froelich-Ammon; N Osheroff
Journal:  Methods Mol Biol       Date:  2001

Review 3.  Cellular roles of DNA topoisomerases: a molecular perspective.

Authors:  James C Wang
Journal:  Nat Rev Mol Cell Biol       Date:  2002-06       Impact factor: 94.444

Review 4.  DNA topoisomerase II as a target for cancer chemotherapy.

Authors:  Jerrylaine V Walker; John L Nitiss
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

5.  Structural basis for gate-DNA recognition and bending by type IIA topoisomerases.

Authors:  Ken C Dong; James M Berger
Journal:  Nature       Date:  2007-12-20       Impact factor: 49.962

Review 6.  DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.

Authors:  John L Nitiss
Journal:  Curr Opin Investig Drugs       Date:  2002-10

Review 7.  Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.

Authors:  V E Anderson; N Osheroff
Journal:  Curr Pharm Des       Date:  2001-03       Impact factor: 3.116

8.  A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.

Authors:  J Dong; J Walker; J L Nitiss
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

9.  DNA repair functions that control sensitivity to topoisomerase-targeting drugs.

Authors:  Mobeen Malik; John L Nitiss
Journal:  Eukaryot Cell       Date:  2004-02

10.  A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells.

Authors:  Jerrylaine V Walker; Karin C Nitiss; Lars H Jensen; Christopher Mayne; Tao Hu; Peter B Jensen; Maxwell Sehested; Tao Hsieh; John L Nitiss
Journal:  J Biol Chem       Date:  2004-03-22       Impact factor: 5.157

View more
  5 in total

Review 1.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

2.  Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.

Authors:  Nicole Stantial; Anna Rogojina; Matthew Gilbertson; Yilun Sun; Hannah Miles; Samantha Shaltz; James Berger; Karin C Nitiss; Sue Jinks-Robertson; John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-12       Impact factor: 11.205

3.  The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Authors:  Brian B Hasinoff; Xing Wu; John L Nitiss; Ragu Kanagasabai; Jack C Yalowich
Journal:  Biochem Pharmacol       Date:  2012-10-05       Impact factor: 5.858

4.  A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.

Authors:  Tim R Blower; Afif Bandak; Amy S Y Lee; Caroline A Austin; John L Nitiss; James M Berger
Journal:  Nucleic Acids Res       Date:  2019-09-05       Impact factor: 16.971

5.  Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.

Authors:  Pan F Chan; Velupillai Srikannathasan; Jianzhong Huang; Haifeng Cui; Andrew P Fosberry; Minghua Gu; Michael M Hann; Martin Hibbs; Paul Homes; Karen Ingraham; Jason Pizzollo; Carol Shen; Anthony J Shillings; Claus E Spitzfaden; Robert Tanner; Andrew J Theobald; Robert A Stavenger; Benjamin D Bax; Michael N Gwynn
Journal:  Nat Commun       Date:  2015-12-07       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.